Depression: EU approves expanded use of esketamine for rapid reduction of symptomsBMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n398 (Published 10 February 2021) Cite this as: BMJ 2021;372:n398
- Elisabeth Mahase
- The BMJ
Esketamine nasal spray—sold under the name Spravato—has been approved by the European Commission as a short term treatment for adults with a moderate to severe episode of major depressive disorder.1
The spray, which must be given alongside an oral antidepressant, has been approved for use in situations deemed a psychiatric emergency, to reduce depressive symptoms rapidly.
The treatment was initially approved by the …